Kristie L. Kahl

A recent survey of physicians revealed that 17 percent of doctors with personal experience with cancer were more likely than those without to act against established guidelines to recommend that low-risk women receive ovarian cancer screening.

In a recent study, researchers from the American Cancer Society found that patients who reported higher satisfaction with their physician’s communication also had better health outcomes at lower costs.

In this special edition of CURE Talks Cancer, we spoke with NFL Hall of Fame quarterback Jim Kelly about his experience with head and neck cancer, and the humbling experience of winning the Jimmy V award for Perseverance at this year’s ESPY Awards.

CURE spoke with Matthew Mossanen, M.D., from the Division of Urology at Brigham and Women’s Hospital, about what Bacillus Calmette-Guérin (BCG) is and what patients should know about this treatment option.

Talazoparib reduced the risk for disease progression or death by 46 percent and improved quality of life compared with chemotherapy in a subgroup of women with breast cancer, according to the phase 3 EMBRACA trial results.

CAR-T cell therapy has been showing promising in treating children with acute lymphoblastic leukemia, but it can come with significant toxicities.

In this week’s episode of CURE Talks Cancer, we spoke with Ethan Hawes about his experience as a 22-year-old diagnosed with multiple myeloma, and his advice for others going through a similar journey.

Individuals diagnosed with a high frequency of basal cell carcinomas, a common type of skin cancer, may be at an increased for developing an unrelated cancer, highlighting the need for additional clinical screening.

Recent research showed first-degree relatives of patients with certain types of blood cancers may be at an increased risk for such disease, highlighting the importance of counseling, gene testing and surveillance.

The combination use of Tumor Treating Fields plus paclitaxel more than doubled progression-free survival, with no serious treatment-related side effects in women with recurrent, platinum-resistant ovarian cancer.

In a global analysis, researchers found global lung cancer mortality rates are projected to increase by 43 percent in women; however, breast cancer rates should decline by 9 percent.

Patients who receive anti-PD-1 therapies may experience delayed cutaneous side effects like lesions, eczema or psoriasis, even after treatment has ended.

In this week’s episode of “CURE® Talks Cancer,” we delve into immunotherapy breakthroughs and how a new series of patient summits can help individuals learn more.

Navigating the career space after a cancer diagnosis can be difficult. We spoke to one professional who can help.

The Food and Drug Administration approved Nivestym (filgrastim-aafi), a biosimilar to Neupogen (filgrastim), for five eligible indications.

In this episode of CURE Talks Cancer, we spoke with a patient, survivor, caregiver and two social workers about the benefits of joining a support group and how they can help individuals through a cancer journey.

"Scanxiety" is common in people with cancer, but is particularly prevalent in those with lung cancer, according to a recent survey.

A national survey demonstrated shared feelings across all blood cancer types about treatment options and their side effects, as well as other social, financial and emotional aspects.

The Food and Drug Administration (FDA) granted a priority review to Keytruda (pembrolizumab) for the treatment of previously treated patients with advanced hepatocellular carcinoma (HCC).

In a recent survey, researchers from the University of Colorado Denver found a variety of predictors that affect caregiver burden, and how psychological resilience and future interventions can help.

We spoke with two members of the Moving Mountains for Multiple Myeloma team.

The American Cancer Society issued an updated guideline recommendation that now calls for screening to begin at age 45 for individuals at average risk for colorectal cancer.

Understanding one’s biomarkers, such as microsatellite stable (MSS) or instable (MSI) status in tumors, is key in understanding how a patient with colorectal cancer may be treated.

The Food and Drug Administration (FDA) granted a priority review to Keytruda (pembrolizumab) in combination with chemotherapy as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC), regardless of PD-L1 expression, according to Merck, the manufacturer of the anti-PD-1 agent.

At the GI Cancer Patient Summit, a panel of caregivers drew upon personal experience to offer advice and discuss what more can be done for individuals in this role of the cancer journey.

We spoke with veteran journalist Neil Canavan about his book, A Cure Within: Scientists Unleashing the Immune System to Kill Cancer.

These discussions should include information about the cancer itself, as well as treatment options, side effects, prognosis, and most importantly, the patient’s values.

In the QUADRA study, treatment with Zejula (niraparib) demonstrated durable responses among women with relapsed or refractory ovarian cancer, regardless of BRCA mutation.

According to findings from the ASCO Annual Meeting, insurance disparities still exist, and may even contribute to cancer-specific and comorbidity-associated mortalities in patients with early-stage non-small cell lung cancer.

Phase 2 study results showed that patients with metastatic or unresectable, FGFR-positive bladder cancer may have a third-line option for treatment.